Argenx (ARGX) announced that Japan’s Ministry of Health, Labour and Welfare, or MHLW, approved Vyvdura for adults with chronic inflammatory demyelinating polyneuropathy. Vyvdura is approved for CIDP as a once weekly 30-to-90 second subcutaneous injection, which can be self-administered at home, and is the first and only neonatal Fc receptor blocker approved for the treatment of CIDP.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx price target raised to $723 from $639 at Wells Fargo
- Argenx price target raised to EUR 740 from EUR 620 at JPMorgan
- Argenx price target raised to EUR 670 from EUR 650 at Barclays
- Argenx price target raised to $706 from $675 at Evercore ISI
- Argenx price target raised to $675 from $646 at Oppenheimer